your project may be unlike any other you have known or seen
iTL will make it happen
Developing and Bringing You the Best Service
Research and Development
Innovation is integral to the iTL mindset. That’s why iTL is constantly engaged in R&D initiatives aimed at expanding the capabilities of our services and improving the quality of our processes. We ensure that we have the most effective technology and tools at our fingertips so that we can consistently and rapidly bring you the best mouse models available.
Expanding Capabilities
Part of the iTL mission is striving to constantly expand our capabilities. Some of the newest and best include:
Hybrid ES Cell Line
iTL developed a hybrid cell line to incorporate the strengths of both the 129SvEv and C57BL/6 lines into a single, more robust ES cell line. The improvements result in more efficient germline transmission, enabling more rapid mouse model production and delivery.
BALB/c ES Cell Line
A new BALB/c ES cell line is in the final stages of development and validation and coming online in Q1 of 2010. This line will provide research programs focused on monoclonal antibody production, immunology, cardiovascular and cancer investigations with new opportunities for gene targeted mouse models.
32 Well Plate
iTL cell culture plates have a unique 32-well format (patent pending) compatible with multi-channel pipettes and automated systems designed for 96-well format. The surface area per well is five times that of a 96-well plate, and comparable to a 24-well plate. They are suitable for any cell and tissue culture applications. This plate design has allowed increases in assay and culturing throughput in conjunction with the precision of automation.
Improving the Process
Assay Development
Our proprietary reporter assays are nontoxic and more robust than commercially available alternatives. The iTL reporter assay combines a cell based and a biochemical assay with imaging capabilities, making it well suited for high throughput screening.
iTL’s biochemical assays include several robust fluorescence assays that support our process development efforts as well as providing tangential capabilities such as in vivo and in vitro measuring of cholesterol metabolism.
The scientists at iTL are always working to improve our services and capabilities. Some technologies currently under development:
Immunological assays: iTL has developed an ELISA kit and DELFIA assay analogue, which measure the activity of novel, biomedically relevant receptors.
Cosmeceutical compounds: Compound (iTL-10I7) was shown to be safe in in vitro assays and human studies and effective at preventing tanning.
